12 August 2023: Clinical Research
Transgastric Jejunostomy (PEG-J) for Continuous Infusion of Levodopa-Carbidopa Intestinal Gel: An Approach for Parkinson’s Disease Treatment
Yusuke Nomoto ABCDEF* , Makoto Furihata ABCDEF , Haruka Hagiwara F , Hirotaka Ishino B , Shintaro Yano D , Hiroki Okawa B , Yoichi Nakatsu B , Kumiko Noda B , Shinjiro Nishi F , Shingo Ogiwara AB , Tsuneo Kitamura D , Taro Osada AGDOI: 10.12659/MSM.941285
Med Sci Monit 2023; 29:e941285
Table 4 Countermeasures for procedure-/device-related adverse events.
| Procedure-related AEs | Events | Countermeasures | ||
|---|---|---|---|---|
| Pneumonia | 2 | Antibiotics | ||
| Peritonitis | 1 | Percutaneous abscess drainage | ||
| Gastric ulcer | 1 | PEG-J replacement | ||
| Hemorrhage | 1 | Spontaneous hemostasis (probably hemorrhage at gastrostomy) | ||
| Skin trouble | 1 | Removal of a PEG-J catheter | ||
| Ileum pulling syndrome | 1 | Removal of a PEG-J catheter | ||
| Infection | 28 | 1 (3.6%) | 23 (82.1%) | 4 (14.3%) |
| Inadvertent removal | 9 | 0 (0.0%) | 0 (0.0%) | 9 (100.0%) |
| Breakage | 7 | 1 (14.3%) | 0 (0.0%) | 6 (85.7%) |
| AEs – adverse events; PEG-J – percutaneous endoscopic transgastric jejunostomy. | ||||